Edition:
United Kingdom

Caroline Humer

UPDATE 4-UnitedHealth profit beats expectations, shares rise

15 Jan 2019

* Company reaffirms 2019 earnings forecast (Adds CEO comment, analyst reaction; updates shares)

U.S. body says gene therapy may be more cost effective for spinal muscular atrophy

21 Dec 2018

NEW YORK/ZURICH Biogen Inc's Spinraza treatment for spinal muscular atrophy and Swiss drugmaker Novartis AG's experimental gene therapy are both expensive, but the gene therapy could be more cost effective once more is known about its U.S. price and long-term success rates, a preliminary report from an independent U.S. nonprofit organization said on Thursday.

U.S body says gene therapy may be more cost effective for spinal muscular atrophy

21 Dec 2018

NEW YORK/ZURICH, Dec 20 Biogen Inc's Spinraza treatment for spinal muscular atrophy and Swiss drugmaker Novartis AG's experimental gene therapy are both expensive, but the gene therapy could be more cost effective once more is known about its U.S. price and long-term success rates, a preliminary report from an independent U.S. nonprofit organization said on Thursday.

Cigna closes $54 billion purchase of Express Scripts

20 Dec 2018

NEW YORK Cigna Corp on Thursday closed its $54-billion (42.65 billion pounds) deal to buy Express Scripts Holding Co, creating one of the biggest providers of pharmacy benefits and insurance plans in the United States, a combination it says will help it improve healthcare coordination and cut costs.

Sign-ups for 2019 Obamacare insurance fall to 8.5 million people

19 Dec 2018

NEW YORK The number of Americans who signed up for 2019 insurance plans created by the Affordable Care Act, often called Obamacare, fell by about 4 percent to 8.5 million people from 2018, the U.S. government said on Wednesday.

CVS to pilot stores with additional floor space for health

29 Nov 2018

NEW YORK CVS Health Corp plans to roll out a handful of pilot stores early next year that will devote more floor space to healthcare services such as nutrition and exercise counseling as well as blood draws, Chief Executive Officer Larry Merlo said on Thursday.

BioMarin sets stage early for hemophilia cure off-Broadway

22 Nov 2018

(This version of the November 21st story has been refiled to show in paragraph 23 that Sangamo Therapeutics has six people in clinical trials)

REFILE-RPT-FOCUS-BioMarin sets stage early for hemophilia cure off-Broadway

21 Nov 2018

NEW YORK, Nov 21 BioMarin Pharmaceutical Inc is turning to the theater to establish its name with hemophilia patients, long before its experimental cure for the bleeding disorder could reach the market.

World News